

Amiodarone

| | |
|---|--|
| Amiodarone dosing may be weight based; ensure accuracy of documented weight before administration | |
| CAUTION: High Administration Risk Rating | |
| Form | 300mg per 10mL prefilled syringe (resuscitation trolley) 150mg per 3mL ampoule |
| Reconstitution | Already in solution |
| Compatibility & Stability | <p>Glucose 5% ONLY Do not over-dilute. Solutions containing less than 300mg amiodarone in 500mL (i.e. less than 600 micrograms per mL) are unstable and should not be used.</p> <p>Incompatible with PVC A non-PVC infusion container (Baxter Viaflo[®], Braun Ecoflac[®]) and a non-PVC infusion set should be used.</p> |
| Administration | <p><u>Slow IV injection – extreme clinical emergency only</u></p> <ul style="list-style-type: none"> Use 300mg per 10 mL prefilled syringe. Does not require further dilution. If prefilled syringe is unavailable the 150mg in 3mL preparation can be used. Dilute to 10mL by adding 300mg (2 ampoules: 6mL) to 4mL glucose 5%. <p>Give over a minimum of 3 minutes. Flush with 10mL of glucose 5%. This should not be repeated for at least 15 minutes. Patient must be closely monitored, e.g. in ICU/CCU/ED setting.</p> <p><u>Intermittent IV infusion (Loading dose)</u> Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely. Dilute required dose in 250mL glucose 5% and infuse over one hour.</p> <p><u>Continuous IV infusion</u> Add required amiodarone dose (usually 900mg, max 1200 mg) to 500mL glucose 5% and infuse using an electronically controlled pump over 23 – 24 hours (900mg) and 24 hours (1200mg).</p> <p>When repeated or continuous infusion is anticipated, administration via a central venous catheter is recommended. The maximum concentration for continuous infusion via peripheral veins is 2mg/mL.</p> |
| Monitoring | <ul style="list-style-type: none"> Blood pressure, heart rate and ECG must be monitored during administration. Should only be administered where facilities exist for cardiac monitoring, defibrillation and cardiac pacing. |
| Extravasation | <ul style="list-style-type: none"> Infusion site reactions may occur, monitor site closely. Extravasation is likely to cause tissue damage. Repeated or continuous infusions should be given via central line. |
| Additional Information | <ul style="list-style-type: none"> Amiodarone is often administered as a loading dose followed by a smaller maintenance dose. |

Information provided relates to Cordarone[®] manufactured by Sanofi, Aurum and Hameln Pharmaceuticals.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542